In the present study, we found that CPT1A-mediated FAO is enhanced in tamoxifen-resistant ER-positive BC cells; in addition, the expression of CPT1A is increased in ER-positive BC patients with recurrence after tamoxifen therapy compared with those with no recurrence after tamoxifen therapy. Here, CPT1A is linked to breast cancer.